Tempest Therapeutics, Inc. SEC filings TPST

Tempest Therapeutics, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Feb 1, 2013. Its latest annual report, Form ARS, was filed on Nov 2, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (officer or director change). The company's fiscal year ends on December 31.

Tempest Therapeutics, Inc. SEC filings
Form Description Filed Period
ARS Annual report to shareholders Nov 2, 2026 Dec 31, 2025
8-K Current report
Officer or director change
Oct 30, 2026 Oct 26, 2026
DEF 14A Proxy statement Oct 26, 2026 Nov 9, 2026
DEFA14A Additional proxy material Oct 20, 2026 —
8-K Current report
Shareholder vote results, Other events
Oct 20, 2026 Oct 14, 2026
8-K Current report
Officer or director change, Regulation FD disclosure
Oct 19, 2026 Oct 13, 2026
PRE 14A Preliminary proxy statement Oct 16, 2026 Nov 9, 2026
D Filing Oct 14, 2026 —
424B3 Prospectus Oct 2, 2026 —
EFFECT Filing Oct 1, 2026 —
8-K Current report
Material agreement, Officer or director change, Regulation FD disclosure
Sep 28, 2026 Sep 22, 2026
S-3 Shelf registration Sep 25, 2026 —
8-K Current report
Material agreement, Regulation FD disclosure
Sep 17, 2026 Sep 14, 2026
DEFA14A Additional proxy material Sep 16, 2026 —
8-K Current report
Shareholder vote results, Other events
Sep 16, 2026 Sep 15, 2026
8-K Current report
Material agreement, Unregistered share sale
Sep 15, 2026 Sep 11, 2026
424B3 Prospectus Sep 1, 2026 —
EFFECT Filing Aug 31, 2026 —
CORRESP Letter to the SEC Aug 27, 2026 —
UPLOAD Letter from the SEC Aug 27, 2026 —
8-K Current report
Officer or director change
Aug 24, 2026 Aug 18, 2026
S-1 Registration statement Aug 21, 2026 —
DEFA14A Additional proxy material Aug 18, 2026 —
8-K Current report
Shareholder vote results, Other events
Aug 18, 2026 Aug 17, 2026
10-Q Quarterly report Aug 13, 2026 Jun 30, 2026
8-K Current report
Results of operations
Aug 13, 2026 Aug 13, 2026
8-K Current report
Material agreement, Unregistered share sale
Aug 13, 2026 Aug 13, 2026
DEFA14A Additional proxy material Jul 28, 2026 —
8-K Current report
Shareholder vote results, Other events
Jul 28, 2026 Jul 27, 2026
8-K Current report
Material agreement, Regulation FD disclosure
Jul 22, 2026 Jul 17, 2026
DEF 14A Proxy statement Jul 17, 2026 Jul 27, 2026
424B3 Prospectus Jul 8, 2026 —
EFFECT Filing Jul 7, 2026 —
PRE 14A Preliminary proxy statement Jul 7, 2026 Jul 27, 2026
CORRESP Letter to the SEC Jul 2, 2026 —
UPLOAD Letter from the SEC Jul 2, 2026 —
S-3 Shelf registration Jun 26, 2026 —
8-K Current report
Shareholder vote results
Jun 23, 2026 Jun 18, 2026
D Filing Jun 23, 2026 —
DEF 14A Proxy statement Jun 8, 2026 Jun 18, 2026
8-K Current report
Officer or director change, Regulation FD disclosure
Jun 4, 2026 May 29, 2026
8-K Current report
Material agreement, Unregistered share sale
Jun 2, 2026 May 28, 2026
PRE 14A Preliminary proxy statement May 29, 2026 Jun 18, 2026
8-K Current report
Officer or director change
May 29, 2026 May 23, 2026
8-K Current report
Listing notice
May 22, 2026 May 19, 2026
8-K Current report
Officer or director change
May 22, 2026 May 22, 2026
10-Q Quarterly report May 14, 2026 Mar 31, 2026
8-K Current report
Results of operations
May 14, 2026 May 14, 2026
8-K Current report
Regulation FD disclosure, Other events
May 6, 2026 May 6, 2026
424B3 Prospectus Apr 10, 2026 —
424B3 Prospectus Apr 10, 2026 —
EFFECT Filing Apr 9, 2026 —
CORRESP Letter to the SEC Apr 8, 2026 —
UPLOAD Letter from the SEC Apr 7, 2026 —
EFFECT Filing Apr 3, 2026 —
D Filing Apr 3, 2026 —
S-3 Shelf registration Apr 2, 2026 —
CORRESP Letter to the SEC Apr 1, 2026 —
UPLOAD Letter from the SEC Apr 1, 2026 —
S-8 POS Filing Mar 31, 2026 —
S-3 Shelf registration Mar 30, 2026 —
S-8 Employee stock plan registration Mar 30, 2026 —
10-K Annual report Mar 30, 2026 Dec 31, 2025
8-K Current report
Results of operations
Mar 30, 2026 Mar 30, 2026
8-K Current report
Material agreement, Unregistered share sale
Mar 23, 2026 Mar 20, 2026
8-K Current report
Regulation FD disclosure, Other events
Feb 25, 2026 Feb 25, 2026
8-K Current report
Regulation FD disclosure
Feb 11, 2026 Feb 11, 2026
8-K Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change in control, Officer or director change
Feb 6, 2026 Feb 3, 2026
8-K Current report
Change to shareholder rights, Officer or director change, Shareholder vote results
Jan 28, 2026 Jan 27, 2026
8-K Current report
Listing notice
Jan 9, 2026 Jan 8, 2026
EFFECT Filing Dec 31, 2025 —
ARS Annual report to shareholders Dec 31, 2025 Dec 31, 2024
DEF 14A Proxy statement Dec 31, 2025 Jan 27, 2026
CORRESP Letter to the SEC Dec 30, 2025 —
CORRESP Letter to the SEC Dec 23, 2025 —
UPLOAD Letter from the SEC Dec 12, 2025 —
S-1 Registration statement Dec 9, 2025 —
PRE 14A Preliminary proxy statement Dec 2, 2025 Dec 31, 2025
8-K Current report
Unregistered share sale, Other events
Nov 26, 2025 Nov 24, 2025
424B5 Prospectus supplement Nov 25, 2025 —
DEFA14A Additional proxy material Nov 19, 2025 —
8-K Current report
Material agreement, Unregistered share sale, Officer or director change, Other events
Nov 19, 2025 Nov 19, 2025
10-Q Quarterly report Nov 5, 2025 Sep 30, 2025
8-K Current report
Results of operations
Nov 5, 2025 Nov 5, 2025
10-Q Quarterly report Aug 11, 2025 Jun 30, 2025
8-K Current report
Results of operations
Aug 11, 2025 Aug 11, 2025
8-K Current report
Material agreement, Regulation FD disclosure, Other events
Jun 12, 2025 Jun 11, 2025
424B5 Prospectus supplement Jun 12, 2025 —
8-K Current report
Other events
Jun 11, 2025 Jun 11, 2025
8-K Current report
Officer or director change
Jun 6, 2025 Jun 5, 2025
10-Q Quarterly report May 13, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 13, 2025 May 13, 2025
10-K/A Amended annual report Apr 30, 2025 Dec 31, 2024
8-K Current report
Other events
Apr 28, 2025 Apr 24, 2025
8-K Current report
Exit or restructuring costs
Apr 18, 2025 Apr 17, 2025
8-K Current report
Agreement ended, Regulation FD disclosure
Apr 9, 2025 Apr 8, 2025
8-K Current report
Change to shareholder rights
Apr 7, 2025 Apr 4, 2025
S-8 Employee stock plan registration Mar 27, 2025 —
10-K Annual report Mar 27, 2025 Dec 31, 2024
8-K Current report
Results of operations
Mar 27, 2025 Mar 27, 2025
424B5 Prospectus supplement Feb 6, 2025 —
EFFECT Filing Jan 27, 2025 —
CORRESP Letter to the SEC Jan 24, 2025 —
S-3/A Filing Jan 24, 2025 —
8-K Current report
Listing notice
Dec 31, 2024 Dec 27, 2024
8-K Current report
Material agreement, Change to shareholder rights, Shareholder vote results
Dec 6, 2024 Dec 3, 2024
DEF 14A Proxy statement Nov 12, 2024 Dec 3, 2024
10-Q Quarterly report Nov 12, 2024 Sep 30, 2024
8-K Current report
Results of operations
Nov 12, 2024 Nov 12, 2024
PRE 14A Preliminary proxy statement Oct 29, 2024 Dec 3, 2024
8-A12B/A Filing Oct 10, 2024 —
8-K Current report
Material agreement, Change to shareholder rights, Other events
Oct 10, 2024 Oct 7, 2024
10-Q Quarterly report Aug 8, 2024 Jun 30, 2024
8-K Current report
Results of operations
Aug 8, 2024 Aug 8, 2024
UPLOAD Letter from the SEC Jul 23, 2024 —
S-3 Shelf registration Jul 19, 2024 —
424B5 Prospectus supplement Jun 20, 2024 —
8-K Current report
Material agreement, Other events
Jun 20, 2024 Jun 20, 2024
8-K Current report
Shareholder vote results
Jun 14, 2024 Jun 13, 2024
10-Q Quarterly report May 9, 2024 Mar 31, 2024
8-K Current report
Results of operations
May 9, 2024 May 9, 2024
ARS Annual report to shareholders Apr 23, 2024 Dec 31, 2023
DEFA14A Additional proxy material Apr 23, 2024 —
DEF 14A Proxy statement Apr 23, 2024 Jun 13, 2024
S-8 Employee stock plan registration Mar 19, 2024 —
10-K Annual report Mar 19, 2024 Dec 31, 2023
8-K Current report
Results of operations
Mar 19, 2024 Mar 19, 2024
S-8 POS Filing Nov 17, 2023 —
S-8 POS Filing Nov 17, 2023 —
S-8 POS Filing Nov 17, 2023 —
S-8 POS Filing Nov 17, 2023 —
S-8 POS Filing Nov 17, 2023 —
S-8 Employee stock plan registration Nov 17, 2023 —
10-Q Quarterly report Nov 8, 2023 Sep 30, 2023
8-K Current report
Results of operations
Nov 8, 2023 Nov 8, 2023
8-K Current report
Other events
Oct 30, 2023 Oct 26, 2023
424B5 Prospectus supplement Oct 12, 2023 —
8-A12B Filing Oct 11, 2023 —
8-K Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Other events
Oct 11, 2023 Oct 10, 2023
8-K Current report
Listing notice
Sep 8, 2023 Sep 6, 2023
8-K Current report
Officer or director change
Sep 7, 2023 Sep 2, 2023
10-Q Quarterly report Aug 10, 2023 Jun 30, 2023
8-K Current report
Results of operations
Aug 10, 2023 Aug 10, 2023
8-K Current report
Officer or director change, Shareholder vote results
Jun 16, 2023 Jun 15, 2023
10-Q Quarterly report May 10, 2023 Mar 31, 2023
8-K Current report
Results of operations
May 10, 2023 May 10, 2023
ARS Annual report to shareholders May 1, 2023 Dec 31, 2022
DEFA14A Additional proxy material May 1, 2023 —
DEF 14A Proxy statement May 1, 2023 Jun 15, 2023
8-K Current report
Other events
Apr 28, 2023 Apr 28, 2023
8-K Current report
Other events
Mar 31, 2023 Mar 31, 2023
10-K Annual report Mar 22, 2023 Dec 31, 2022
8-K Current report
Results of operations
Mar 22, 2023 Mar 22, 2023
8-K Current report
Material agreement, New debt
Dec 29, 2022 Dec 23, 2022
10-Q Quarterly report Nov 8, 2022 Sep 30, 2022
8-K Current report
Results of operations
Nov 8, 2022 Nov 8, 2022
8-K Current report
Officer or director change
Sep 23, 2022 Sep 19, 2022
10-Q Quarterly report Aug 15, 2022 Jun 30, 2022
8-K Current report
Results of operations
Aug 15, 2022 Aug 15, 2022
S-8 Employee stock plan registration Jun 21, 2022 —
8-K Current report
Officer or director change, Shareholder vote results
Jun 21, 2022 Jun 17, 2022
8-K Current report
Other events
Jun 9, 2022 Jun 9, 2022
EFFECT Filing May 27, 2022 —
424B3 Prospectus May 27, 2022 —
8-K Current report
Other events
May 26, 2022 May 26, 2022
DEFA14A Additional proxy material May 26, 2022 —
CORRESP Letter to the SEC May 24, 2022 —
UPLOAD Letter from the SEC May 18, 2022 —
S-3 Shelf registration May 16, 2022 —
S-8 Employee stock plan registration May 13, 2022 —
10-Q Quarterly report May 13, 2022 Mar 31, 2022
8-K Current report
Results of operations
May 13, 2022 May 13, 2022
D Filing May 11, 2022 —
DEFA14A Additional proxy material May 9, 2022 —
DEFA14A Additional proxy material May 9, 2022 —
DEFA14A Additional proxy material May 2, 2022 —
DEF 14A Proxy statement May 2, 2022 Jun 17, 2022
8-K Current report
Material agreement, Unregistered share sale, Other events
May 2, 2022 Apr 26, 2022
PRE 14A Preliminary proxy statement Apr 22, 2022 Jun 17, 2022
424B5 Prospectus supplement Apr 14, 2022 —
10-K/A Amended annual report Apr 1, 2022 Dec 31, 2021
10-K Annual report Mar 29, 2022 Dec 31, 2021
8-K Current report
Results of operations
Mar 29, 2022 Mar 29, 2022
8-K Current report
Officer or director change
Dec 23, 2021 Dec 20, 2021
10-Q Quarterly report Nov 10, 2021 Sep 30, 2021
8-K Current report
Results of operations
Nov 10, 2021 Nov 10, 2021
8-K/A Amended current report
Officer or director change
Sep 30, 2021 Jul 12, 2021
8-K Current report
Bylaw or fiscal year change
Sep 24, 2021 Sep 21, 2021
10-Q Quarterly report Aug 12, 2021 Jun 30, 2021
8-K Current report
Results of operations, Officer or director change
Aug 12, 2021 Aug 12, 2021
EFFECT Filing Jul 23, 2021 —
8-K Current report
Other events
Jul 23, 2021 Jul 23, 2021
424B5 Prospectus supplement Jul 23, 2021 —
CORRESP Letter to the SEC Jul 22, 2021 —
UPLOAD Letter from the SEC Jul 21, 2021 —
S-3 Shelf registration Jul 16, 2021 —
8-K Current report
Other events
Jul 16, 2021 Jul 16, 2021
8-K Current report
Officer or director change
Jul 12, 2021 Jul 12, 2021
8-K Current report
Officer or director change
Jul 7, 2021 Jul 1, 2021
S-8 Employee stock plan registration Jul 7, 2021 —

Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
TPST (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Brisbane, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1544227
Former names
Millendo Therapeutics, Inc. (until Jul 1, 2021); OvaScience, Inc. (until Dec 6, 2018)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.